BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Prognosis
18 results:

  • 1. A rare KMT2A::cbl transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
    Yu J; Song F; Zhang M; Xiao P; Feng J; Hong R; Hu Y; Huang H; Wei G
    Mol Biol Rep; 2024 Apr; 51(1):561. PubMed ID: 38643442
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
    Tefferi A; Gangat N; Pardanani A; Crispino JD
    Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
    Lafage-Pochitaloff M; Gerby B; Baccini V; Largeaud L; Fregona V; Prade N; Juvin PY; Jamrog L; Bories P; Hébrard S; Lagarde S; Mansat-De Mas V; Dovey OM; Yusa K; Vassiliou GS; Jansen JH; Tekath T; Rombaut D; Ameye G; Barin C; Bidet A; Boudjarane J; Collonge-Rame MA; Gervais C; Ittel A; Lefebvre C; Luquet I; Michaux L; Nadal N; Poirel HA; Radford-Weiss I; Ribourtout B; Richebourg S; Struski S; Terré C; Tigaud I; Penther D; Eclache V; Fontenay M; Broccardo C; Delabesse E
    Blood Adv; 2022 Jan; 6(2):386-398. PubMed ID: 34638130
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.
    Li X; Shao Y; Sheng L; Zhu J; Wang Z; Guo K; Sun L
    Cancer Med; 2021 Feb; 10(3):974-988. PubMed ID: 33405390
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
    Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN
    BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
    Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
    Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. C-cbl and cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
    Luo P; Wang X; Zhou J; Li L; Jing Z
    Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma.
    Sun P; Chen C; Xia Y; Bi X; Liu P; Zhang F; Yang H; An X; Jiang W; Wang F
    Dis Markers; 2017; 2017():6570808. PubMed ID: 28676731
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma.
    Cong M; Li J; Jing R; Li Z
    Tumour Biol; 2016 Jul; 37(7):9441-50. PubMed ID: 26781978
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The genomic landscape of juvenile myelomonocytic leukemia.
    Stieglitz E; Taylor-Weiner AN; Chang TY; Gelston LC; Wang YD; Mazor T; Esquivel E; Yu A; Seepo S; Olsen S; Rosenberg M; Archambeault SL; Abusin G; Beckman K; Brown PA; Briones M; Carcamo B; Cooper T; Dahl GV; Emanuel PD; Fluchel MN; Goyal RK; Hayashi RJ; Hitzler J; Hugge C; Liu YL; Messinger YH; Mahoney DH; Monteleone P; Nemecek ER; Roehrs PA; Schore RJ; Stine KC; Takemoto CM; Toretsky JA; Costello JF; Olshen AB; Stewart C; Li Y; Ma J; Gerbing RB; Alonzo TA; Getz G; Gruber T; Golub T; Stegmaier K; Loh ML
    Nat Genet; 2015 Nov; 47(11):1326-1333. PubMed ID: 26457647
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.
    Padron E; Garcia-Manero G; Patnaik MM; Itzykson R; Lasho T; Nazha A; Rampal RK; Sanchez ME; Jabbour E; Al Ali NH; Thompson Z; Colla S; Fenaux P; Kantarjian HM; Killick S; Sekeres MA; List AF; Onida F; Komrokji RS; Tefferi A; Solary E
    Blood Cancer J; 2015 Jul; 5(7):e333. PubMed ID: 26230957
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a cbl/cbl-b deficiency-driven murine model of myeloproliferative disorders.
    William BM; An W; Feng D; Nadeau S; Mohapatra BC; Storck MA; Band V; Band H
    Hematology; 2016 May; 21(4):218-24. PubMed ID: 26177294
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
    Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
    PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Activating cbl mutations are associated with a distinct MDS/MPN phenotype.
    Schwaab J; Ernst T; Erben P; Rinke J; Schnittger S; Ströbel P; Metzgeroth G; Mossner M; Haferlach T; Cross NC; Hochhaus A; Hofmann WK; Reiter A
    Ann Hematol; 2012 Nov; 91(11):1713-20. PubMed ID: 23010802
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Comparison of prognosis of skull base chordoma treated by surgical resection and gamma knife surgery].
    Shu Z; Hou Y; Wang Y; Tang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Apr; 36(4):359-62. PubMed ID: 21566291
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
    Sulzbacher I; Birner P; Trieb K; Träxler M; Lang S; Chott A
    Mod Pathol; 2003 Jan; 16(1):66-71. PubMed ID: 12527715
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Circulating macrophage colony stimulating factor as a marker of tumour progression.
    McDermott RS; Deneux L; Mosseri V; Védrenne J; Clough K; Fourquet A; Rodriguez J; Cosset JM; Sastre X; Beuzeboc P; Pouillart P; Scholl SM
    Eur Cytokine Netw; 2002; 13(1):121-7. PubMed ID: 11956031
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.